ReNeuron’s stem cell treatment fails a small stroke study, but the biotech says it’s ready for pivotal
ReNeuron’s mid-stage stem cell study on stroke disability failed to hit a modest primary endpoint. But after stretching and twisting to reach what it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
